KELLOKUMPU-LEHTINEN, PIRKKO-LIISA et al
"Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial." Anticancer Research
40.12
(2020):
6915-6921.
Web. 19 April. 2024.